Included in the formulation
АТХ:V.09.C.A Compounds of technetium 99m
Pharmacodynamics:The drug accumulates in the cells of the proximal parts of the convoluted tubules of the kidneys.
Pharmacokinetics:After intravenous injection quickly leaves the vascular bed, in 3-5 minutes the concentration in the blood plasma is not more than 2%. The maximum concentration in the kidney is reached after 6 minutes and remains for 2 hours.
The half-life is 6 hours. Elimination by the kidneys.
Indications:It is used to diagnose blood flow in the kidneys.
XVIII.R90-R94.R93.4 Deviations from the norm, detected when obtaining a diagnostic image during the study of urinary organs
XXI.Z00-Z13.Z03 Medical surveillance and evaluation in case of suspected disease or pathological condition
Contraindications:Individual intolerance.
Pregnancy and lactation:Recommendations for FDA - Category C. Contraindicated in pregnancy. Breastfeeding should refrain from breastfeeding for 24 hours after the study.
Dosing and Administration:Intravenously at 1.5 MBq / kg 4 hours after eating.
The highest daily dose: 1.5 MBq / kg.
The highest single dose: 1.5 MBq / kg.
Side effects:Nausea, fever, impaired sense of smell, transient leukocytosis.
Allergic reactions.
Overdose:Arterial hypotension, dyspnea.
Treatment is symptomatic.
Interaction:When used simultaneously with blockers of slow calcium channels and β-adrenoblockers, it is possible to obtain false negative test results.
Special instructions:The use of the drug is possible only in a specialized hospital.